Gland Pharma’s Board has approved the appointment of Shyamakant Giri, as the new Chief Executive Officer (CEO) of the company. Giri is expected to join the company with effect from January 15, 2025.

Giri is a business leader with over 25 years of strategic and operating experience in pharmaceuticals, devices, diagnostics and healthcare services in leading Indian and multinational organisations across Asia, Africa, MENA & LATAM markets.

He possesses rich experience in creating new ventures and improving existing businesses, developing leaders, identifying opportunities for value creation, and executing with discipline. His specialties include Business Development, Operations, Strategy, Product Marketing, startups, and turnarounds.

Giri is currently the President (India Business & Emerging Markets) of Amneal Pharmaceuticals, responsible for the commercial expansion and growth in India and Rest of the World markets. Previously, Giri was associated with Rivaara Labs as the Chief Executive Officer. Earlier, Giri was associated in various roles with Abbott India, AbbVie (India Region) and Abbott Diagnostics for almost eighteen years (2002-2020).

Giri started his professional career with Wockhardt and was associated during the period 1999-2002. Giri has done his Master’s in Marketing Management from Jamnalal Bajaj Institute of Management Studies and also holds a Master’s degree in Science (Organic Chemistry) from Mumbai University. He completed his Executive Programme from INSEAD, Singapore and Executive Programme in Hospital Management from Indian Institute of Management, Ahmedabad.

Srinivas Sadu will continue to be the Executive Chairman of the company and support the company’s next phase of growth.